
Wellington Management Closes $393M Biomedical Innovation Fund
The firm will invest in biotech companies focused on drug discovery and development.
Wellington Management
The close of the fund expands Wellington’s private investment platform which totals $2.7 billion. The new funding will be used to help the companies advance their scientific program.
“Biotechnology represents an exciting investment area, driven by an explosion in fundamental biomedical knowledge and a growing ability to deploy that knowledge in the service of breakthrough drug discovery,” said Bob Deresiewicz, M.D., senior managing director at Wellington, an independent investment management firm.
Wellington leverages its biomedical, scientific and industry knowledge to identify assets that could advance medical practice, Deresiewicz said.
Inside Digital Health™ reached out to Wellington Management to learn more about the close the fund but could not get a hold of anyone.
This is not the firm’s first healthcare investment either. Back in July, Wellington Management led a
Wellington’s $393 million fund adds to the
The fund also follows the
As 2019 comes to a close, funding in health-tech is shaping up to end the year
Get the best insights in digital health
Related








































